VNRX Share Price Performance
US$0.33
-0.48 (-59.54%)
Price US$0.33
Share Pricen/a
VolitionRx Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
VNRX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
VolitionRx Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.19
- 100.00%
- -1,554.31%
- -28.6%
About VNRX
- Founded
- n/a
- Employees
- 70
- CEO
- WebsiteView website
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.
